8 juli 2012: aanvullend op onderstaand persbericht van Reuters uit 2009 hier het abstract van een studie die bevestigt dat BCRA 1 en BCRA 2 bij mannen met prostaatkanker een onafhankelijke prognose geeft van groter risico op overlijden aan prostaatkanker als zij prostaatkanker krijgen: Germline BRCA mutations denote a clinicopathologic subset of prostate cancer. Met als conclusie: BRCA2 mutation carriers had an increased risk of prostate cancer and a higher histologic grade, and BRCA1 or BRCA2 mutations were associated with a more aggressive clinical course. These results may have implications for tailoring clinical management of this subset of hereditary prostate cancer. Abstract van de studie plus referentielijst staat onderaan.

Hier het abstract van een andere studie. Het volledige studierapport: Decreased prostate cancer-specific survival of men with BRCA2 mutations from multiple breast cancer families is tegen betaling in te zien op de website van Cancer Prevention research.

2011 Jul;4(7):1002-10.

Decreased prostate cancer-specific survival of men with BRCA2 mutations from multiple breast cancer families.


kConFab, Research Department, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia, 3002. heather.thorne@petermac.org.


The role of a germ-line BRCA2 mutation in the development of prostate cancer is established, but the clinical presentation linked to outcome for this group of men has not been well described. A total of 148 men from 1,423 families were ascertained from the kConFab consortium. Each participant met the following criteria: (i) a verified case of prostate cancer; (ii) confirmed as either a carrier or noncarrier of a family-specific BRCA pathogenic mutation; (iii) comprehensive clinical and treatment data were available. Clinical data were linked to treatment received and overall survival was analyzed by Kaplan-Meier. Prostate cancer in men from breast cancer-prone families has a high risk of disease progression, irrespective of mutation status. BRCA2 mutation carriers have an increased risk of death and prostate cancer-related death [HR (95% CI) 4.5 (2.12-9.52), P = 8.9 × 10(-5)] by comparison with noncarriers. Serum PSA readings taken prior to diagnosis in 90% of all men, age adjusted, were above clinical significance. Following D'Amico risk stratification, 77.5% of BRCA2 mutation carriers and 58.7% of noncarriers had high-risk disease. BRCA2 mutation status was also an independent prognostic indicator of overall survival. Furthermore, there was a poor overall survival outcome for both the BRCA2 mutation carriers and noncarriers given curative-intent treatment. All men in breast cancer-prone families are at risk of developing aggressive prostate cancer. This information is significant and should be included in discussions with genetic counselors and medical professionals when discussing prostate cancer treatment options for men in these families, irrespective of mutation status.

[PubMed - indexed for MEDLINE]


1 februari 2009: Bron: Reuters

Prostaatkankerpatienten die drager zijn van het BRCA 1 en BRCA 2 borstkankergen hebben meestal een agressieverer vorm van prostaatkanker. Prostaatkankerpatienten die nog een beginnend stadiumj van kanker hebben doen er goed aan een test uit te laten voeren op het wel of niet drager zijn van het BRCA gen want een wait and see beleid lijkt voor deze prostaatkankerpatienten een te groot risico, aldus onderzoekers van onderstaande studie.

Breast cancer mutation raises prostate risks in men

Thu Jan 29, 2009 12:03pm EST


WASHINGTON, Jan 29 (Reuters) - The so-called breast cancer genes BRCA1 and BRCA2 can raise the risk that a man who develops prostate cancer will get an aggressive form of the disease, U.S. researchers reported on Thursday.

Certain mutations in the genes indicated a man was at risk of more aggressive cancer and should be treated right away, the team at the Albert Einstein College of Medicine of Yeshiva University said.

Their study of 2,000 Jewish men shows the gene mutation, more common among Jews of European descent, might help show which men have a slow-growing tumor that may not need immediate treatment.

"One of the biggest problems with early-stage prostate cancer is being able to distinguish between tumors with the potential to become aggressive and those that may persist for many years without enlarging or spreading," said Dr. Robert Burk, who led the study.

He said Ashkenazi Jewish men diagnosed with early-stage prostate cancer might want to consider getting tested for the mutations in BRCA2 and BRCA1.

"Our large study shows conclusively that prostate cancer patients with either the BRCA2 gene mutation or the BRCA1-185delAG mutation are more susceptible to aggressive cancers than people without that mutation," Burk added in a statement.

For their study, Burk and colleagues tested 979 men with prostate cancer and 1,251 men without it for BRCA1 and BRCA2, both rare genetic mutations known in women to raise the risk of breast and ovarian cancers considerably.

Men with any one of three mutations in the two genes were not any more likely to be in the prostate cancer group. But, if they did have one, their cancer was much more likely to be of an aggressive type, Burk's team reported in Clinical Cancer Research.

Prostate cancer is the second-leading cancer killer of men, killing 221,000 every year globally, with 679,000 new cases diagnosed.

It is easily cured in early stages with surgery or radiation and some men have such slow-growing tumors that they are advised not to have any treatment at all. But distinguishing between the two is tricky and doctors welcome any new tools they can use to guide them.

(Reporting by Maggie Fox; Editing by Michael Kahn and Jackie Frank)


[-] Text [+]

BRCA2 mutation carriers had an increased risk of prostate cancer and a higher histologic grade, and BRCA1 or BRCA2 mutations were associated with a more aggressive clinical course. These results may have implications for tailoring clinical management of this subset of hereditary prostate cancer

2010 Apr 1;16(7):2115-21. Epub 2010 Mar 9.

Germline BRCA mutations denote a clinicopathologic subset of prostate cancer.


Clinical Genetics Service, Department of Medicine, Urology Service, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.



Increased prostate cancer risk has been reported for BRCA mutation carriers, but BRCA-associated clinicopathologic features have not been clearly defined.


We determined BRCA mutation prevalence in 832 Ashkenazi Jewish men diagnosed with localized prostate cancer between 1988 and 2007 and 454 Ashkenazi Jewish controls and compared clinical outcome measures among 26 BRCA mutation carriers and 806 noncarriers. Kruskal-Wallis tests were used to compare age of diagnosis and Gleason score, and logistic regression models were used to determine associations between carrier status, prostate cancer risk, and Gleason score. Hazard ratios (HR) for clinical end points were estimated using Cox proportional hazards models.


BRCA2 mutations were associated with a 3-fold risk of prostate cancer [odds ratio, 3.18; 95% confidence interval (95% CI), 1.52-6.66; P = 0.002] and presented with more poorly differentiated (Gleason score > or =7) tumors (85% versus 57%; P = 0.0002) compared with non-BRCA-associated prostate cancer. BRCA1 mutations conferred no increased risk. After 7,254 person-years of follow-up, and adjusting for clinical stage, prostate-specific antigen, Gleason score, and treatment, BRCA2 and BRCA1 mutation carriers had a higher risk of recurrence [HR (95% CI), 2.41 (1.23-4.75) and 4.32 (1.31-13.62), respectively] and prostate cancer-specific death [HR (95% CI), 5.48 (2.03-14.79) and 5.16 (1.09-24.53), respectively] than noncarriers.


BRCA2 mutation carriers had an increased risk of prostate cancer and a higher histologic grade, and BRCA1 or BRCA2 mutations were associated with a more aggressive clinical course. These results may have implications for tailoring clinical management of this subset of hereditary prostate cancer.

Copyright 2010 AACR.

[PubMed - indexed for MEDLINE]


    1. Witte JS
    . Prostate cancer genomics: towards a new understanding. Nat Rev Genet 2009;10:7782.
    1. Thompson D,
    2. Easton DF
    . Cancer incidence in BRCA1 mutation carriers. J Natl Cancer Inst 2002;94:135865.
    1. Struewing JP,
    2. Hartge P,
    3. Wacholder S,
    4. et al
    . The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997;336:14018.
    1. Warner E,
    2. Foulkes W,
    3. Goodwin P,
    4. et al
    . Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer. J Natl Cancer Inst 1999;91:12417.
    1. Robson M,
    2. Offit K
    . Clinical practice. Management of an inherited predisposition to breast cancer. N Engl J Med 2007;357:15462.
    1. Gayther SA,
    2. de Foy KA,
    3. Harrington P,
    4. et al
    . The frequency of germ-line mutations in the breast cancer predisposition genes BRCA1 and BRCA2 in familial prostate cancer. The Cancer Research Campaign/British Prostate Group United Kingdom Familial Prostate Cancer Study Collaborators. Cancer Res 2000;60:45138.
    1. Kirchhoff T,
    2. Kauff ND,
    3. Mitra N,
    4. et al
    . BRCA mutations and risk of prostate cancer in Ashkenazi Jews. Clin Cancer Res 2004;10:291821.
    1. Brose MS,
    2. Rebbeck TR,
    3. Calzone KA,
    4. Stopfer JE,
    5. Nathanson KL,
    6. Weber BL
    . Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst 2002;94:136572.
    1. Gleason DF,
    2. Mellinger GT
    . Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. 1974. J Urol 2002;167:9538; discussion 59.
    1. Bostwick DG
    . Gleason grading of prostatic needle biopsies. Correlation with grade in 316 matched prostatectomies. Am J Surg Pathol 1994;18:796803.
    1. Bahnson RR,
    2. Hanks GE,
    3. Huben RP,
    4. et al
    . NCCN practice guidelines for prostate cancer. Oncology 2000;14:1119.
    1. Tryggvadottir L,
    2. Vidarsdottir L,
    3. Thorgeirsson T,
    4. et al
    . Prostate cancer progression and survival in BRCA2 mutation carriers. J Natl Cancer Inst 2007;99:92935.
    1. Mitra A,
    2. Fisher C,
    3. Foster CS,
    4. et al
    . Prostate cancer in male BRCA1 and BRCA2 mutation carriers has a more aggressive phenotype. Br J Cancer 2008;98:5027.
    1. Narod SA,
    2. Neuhausen S,
    3. Vichodez G,
    4. et al
    . Rapid progression of prostate cancer in men with a BRCA2 mutation. Br J Cancer 2008;99:3714.
    1. Agalliu I,
    2. Gern R,
    3. Leanza S,
    4. Burk RD
    . Associations of high-grade prostate cancer with BRCA1 and BRCA2 founder mutations. Clin Cancer Res 2009;15:111220.
    1. Giusti RM,
    2. Rutter JL,
    3. Duray PH,
    4. et al
    . A twofold increase in BRCA mutation related prostate cancer among Ashkenazi Israelis is not associated with distinctive histopathology. J Med Genet 2003;40:78792.
    1. Willems AJ,
    2. Dawson SJ,
    3. Samaratunga H,
    4. et al
    . Loss of heterozygosity at the BRCA2 locus detected by multiplex ligation-dependent probe amplification is common in prostate cancers from men with a germline BRCA2 mutation. Clin Cancer Res 2008;14:295361.
    1. Mitchell MK,
    2. Gregersen PK,
    3. Johnson S,
    4. Parsons R,
    5. Vlahov D
    . The New York Cancer Project: rationale, organization, design, and baseline characteristics. J Urban Health 2004;81:30110.
    1. Stephenson AJ,
    2. Kattan MW,
    3. Eastham JA,
    4. et al
    . Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. J Clin Oncol 2006;24:39738.
    1. Nielsen ME,
    2. Makarov DV,
    3. Humphreys E,
    4. Mangold L,
    5. Partin AW,
    6. Walsh PC
    . Is it possible to compare PSA recurrence-free survival after surgery and radiotherapy using revised ASTRO criterion—“nadir + 2”? Urology 2008;72:38993; discussion 94.
    1. Thompson KE,
    2. Hernandez J,
    3. Canby-Hagino ED,
    4. Troyer D,
    5. Thompson IM
    . Prognostic features in men who died of prostate cancer. J Urol 2005;174:5536; discussion 56.
    1. Kaplan EL,
    2. Meier P
    . Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:45781.
    1. Cox DR
    . Regression models and life-tables (with discussion). J R Stat Soc B 1972;34:187220.
    1. Schoenfeld D
    . Partial residuals for the proportional hazards regression model. Biometrika;69:23941.
    1. Hubert A,
    2. Peretz T,
    3. Manor O,
    4. et al
    . The Jewish Ashkenazi founder mutations in the BRCA1/BRCA2 genes are not found at an increased frequency in Ashkenazi patients with prostate cancer. Am J Hum Genet 1999;65:9214.
    1. Lehrer S,
    2. Fodor F,
    3. Stock RG,
    4. et al
    . Absence of 185delAG mutation of the BRCA1 gene and 6174delT mutation of the BRCA2 gene in Ashkenazi Jewish men with prostate cancer. Br J Cancer 1998;78:7713.
    1. Nastiuk KL,
    2. Mansukhani M,
    3. Terry MB,
    4. et al
    . Common mutations in BRCA1 and BRCA2 do not contribute to early prostate cancer in Jewish men. Prostate 1999;40:1727.
    1. Vazina A,
    2. Baniel J,
    3. Yaacobi Y,
    4. et al
    . The rate of the founder Jewish mutations in BRCA1 and BRCA2 in prostate cancer patients in Israel. Br J Cancer 2000;83:4636.
  1. Cancer risks in BRCA2 mutation carriers. The Breast Cancer Linkage Consortium. J Natl Cancer Inst 1999;91:13106.
    1. Agalliu I,
    2. Karlins E,
    3. Kwon EM,
    4. et al
    . Rare germline mutations in the BRCA2 gene are associated with early-onset prostate cancer. Br J Cancer 2007;97:82631.
    1. Thompson IM,
    2. Pauler DK,
    3. Goodman PJ,
    4. et al
    . Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med 2004;350:223946.
    1. Fowler JE Jr.,
    2. Bigler SA,
    3. Bowman G,
    4. Kilambi NK
    . Race and cause specific survival with prostate cancer: influence of clinical stage, Gleason score, age and treatment. J Urol 2000;163:13742.
    1. Chu KC,
    2. Tarone RE,
    3. Freeman HP
    . Trends in prostate cancer mortality among black men and white men in the United States. Cancer 2003;97:150716.
    1. Rodriguez C,
    2. Jacobs EJ,
    3. Patel AV,
    4. et al
    . Jewish ethnicity and prostate cancer mortality in two large US cohorts. Cancer Causes Control 2002;13:2717.
    1. Mani RS,
    2. Tomlins SA,
    3. Callahan K,
    4. et al
    . Induced chromosomal proximity and gene fusions in prostate cancer. Science 2009;326:1230.
    1. Luedeke M,
    2. Linnert CM,
    3. Hofer MD,
    4. et al
    . Predisposition for TMPRSS2-ERG fusion in prostate cancer by variants in DNA repair genes. Cancer Epidemiol Biomarkers Prev 2009;18:30305.
    1. Scher HI,
    2. Heller G
    . Clinical states in prostate cancer: toward a dynamic model of disease progression. Urology 2000;55:3237.
    1. Stephenson AJ,
    2. Scardino PT,
    3. Eastham JA,
    4. et al
    . Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst 2006;98:7157.
    1. Quaye L,
    2. Gayther SA,
    3. Ramus SJ,
    4. et al
    . The effects of common genetic variants in oncogenes on ovarian cancer survival. Clin Cancer Res 2008;14:58339.
    1. Gaudet MM,
    2. Hunter K,
    3. Pharoah P,
    4. et al
    . Genetic variation in SIPA1 in relation to breast cancer risk and survival after breast cancer diagnosis. Int J Cancer 2008.
    1. Ashworth A
    . Drug resistance caused by reversion mutation. Cancer Res 2008;68:100213.
    1. King M-C,
    2. Marks JH,
    3. Mandell JB
    . Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003;302:6436.

Plaats een reactie ...

Reageer op "BCRA 1 en BCRA 2: prostaatkankerpatienten die drager zijn van het borstkankergen BRCA 1 of BRCA 2 hebben agressievere vorm van prostaatkanker en significant meer kans op overlijden."

Gerelateerde artikelen